Anti-Mouse Ly6C Antibody (Monts 1) is a rat-derived anti-mouse Ly6C IgG2a type antibody inhibitor. Anti-Mouse Ly6C Antibody (Monts 1) depletes monocytes, neutrophils, and some other granulocyte populations. Anti-Mouse Ly6C Antibody (Monts 1) can be used for the researches of cancer, immunology and infection, such as chikungunya ( CHIKV ) and aggressive tumor [1] [2] [3].
In Vivo, Anti-Mouse Ly6C Antibody (Monts 1) (200 μg, i.p., once a week for 4 weeks) reverses anti-PD-1/CTLA-4 immunotherapy resistance in aggressive KP 344SQ tumor mice models[1]. Anti-Mouse Ly6C Antibody (Monts 1) (700 μg, i.p., 24 h prior to infection) reduces chikungunya (CHIKV) infection in the skin and subsequent dissemination in CHIKV mice models[2]. Anti-Mouse Ly6C Antibody (Monts 1) (70 μg, Subconjuctivally administration, 7 days before infection) depletes macrophages in Herpes Simplex Virus-1-induced subclinical corneal inflammation[3].
In Vitro, The antibody framework is stable, specific and adaptable, and has the ability to bind both antigens and endogenous immune receptors. Monoclonal antibodies have several derivatives, including bispecific antibodies, antibody-drug conjugates, and antibody fragments, and have significant effects in fields such as immunology and oncology. When designing inhibitory antibodies, considerations include identification of antigen-specific variable regions, choice of expression system, use of multispecific formats, and antibody derivatives based on fragmentation, oligomerization, or conjugation with other functional moieties[1].
References:
[1]. Rodriguez BL, et al. Targeting immunosuppressive Ly6C+ classical monocytes reverses anti-PD-1/CTLA-4 immunotherapy resistance. Front Immunol. 2023 Jun 28;14:1161869.
[2]. Holmes AC, et al. Ly6C+ monocytes in the skin promote systemic alphavirus dissemination. Cell Rep. 2024 Mar 26;43(3):113876.
[3]. Rowe AM, et al. Subclinical Herpes Simplex Virus Type 1 Infections Provide Site-Specific Resistance to an Unrelated Pathogen. J Immunol. 2017 Feb 15;198(4):1706-1717.
In Vivo, Anti-Mouse Ly6C Antibody (Monts 1) (200 μg, i.p., once a week for 4 weeks) reverses anti-PD-1/CTLA-4 immunotherapy resistance in aggressive KP 344SQ tumor mice models[1]. Anti-Mouse Ly6C Antibody (Monts 1) (700 μg, i.p., 24 h prior to infection) reduces chikungunya (CHIKV) infection in the skin and subsequent dissemination in CHIKV mice models[2]. Anti-Mouse Ly6C Antibody (Monts 1) (70 μg, Subconjuctivally administration, 7 days before infection) depletes macrophages in Herpes Simplex Virus-1-induced subclinical corneal inflammation[3].
In Vitro, The antibody framework is stable, specific and adaptable, and has the ability to bind both antigens and endogenous immune receptors. Monoclonal antibodies have several derivatives, including bispecific antibodies, antibody-drug conjugates, and antibody fragments, and have significant effects in fields such as immunology and oncology. When designing inhibitory antibodies, considerations include identification of antigen-specific variable regions, choice of expression system, use of multispecific formats, and antibody derivatives based on fragmentation, oligomerization, or conjugation with other functional moieties[1].
References:
[1]. Rodriguez BL, et al. Targeting immunosuppressive Ly6C+ classical monocytes reverses anti-PD-1/CTLA-4 immunotherapy resistance. Front Immunol. 2023 Jun 28;14:1161869.
[2]. Holmes AC, et al. Ly6C+ monocytes in the skin promote systemic alphavirus dissemination. Cell Rep. 2024 Mar 26;43(3):113876.
[3]. Rowe AM, et al. Subclinical Herpes Simplex Virus Type 1 Infections Provide Site-Specific Resistance to an Unrelated Pathogen. J Immunol. 2017 Feb 15;198(4):1706-1717.